NEW YORK (GenomeWeb News) — Ciphergen and Quest Diagnostics plan to jointly develop a blood-based test for the detection of peripheral artery disease.
 
The deal is the second of a three-part alliance the firms formed last year in which Quest will use Ciphergen’s SELDI-based ProteinChip technology to create the test. The first incarnation resulted in a test that triages ovarian cancer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.